A Randomized, Open Label, 2-Period, 2-Treatment, Cross-over Phase 1 Study to Evaluate the Bio-equivalence of Single Oral Dose of TAK-536 Pediatric Formulation and TAK-536 Commercial Formulation in Healthy Adult Male Subjects

Trial Profile

A Randomized, Open Label, 2-Period, 2-Treatment, Cross-over Phase 1 Study to Evaluate the Bio-equivalence of Single Oral Dose of TAK-536 Pediatric Formulation and TAK-536 Commercial Formulation in Healthy Adult Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Azilsartan (Primary)
  • Indications Essential hypertension; Hypertension
  • Focus Pharmacokinetics
  • Sponsors Takeda
  • Most Recent Events

    • 29 Jun 2017 Planned number of patients changed from 14 to 28.
    • 29 Jun 2017 Status changed from recruiting to completed.
    • 06 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top